XTRA:CURK

Stock Analysis Report

Executive Summary

curasan AG, together with its subsidiaries, develops, produces, and markets biomaterials and medical devices for bone and tissue regeneration worldwide.

Snowflake

Fundamentals

Mediocre balance sheet and slightly overvalued.

Share Price & News

How has curasan's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-4.0%

CURK

1.3%

DE Biotechs

3.9%

DE Market


1 Year Return

-58.2%

CURK

1.7%

DE Biotechs

3.4%

DE Market

Return vs Industry: CURK underperformed the German Biotechs industry which returned 1.7% over the past year.

Return vs Market: CURK underperformed the German Market which returned 3.4% over the past year.


Shareholder returns

CURKIndustryMarket
7 Day-4.0%1.3%3.9%
30 Day-7.2%-5.0%2.1%
90 Day-11.7%-4.5%3.7%
1 Year-57.7%-58.2%1.8%1.7%6.7%3.4%
3 Year-62.5%-65.7%69.2%67.5%18.9%8.6%
5 Year-70.6%-73.1%14.0%11.5%41.8%22.5%

Price Volatility Vs. Market

How volatile is curasan's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is curasan undervalued compared to its fair value and its price relative to the market?

38.8%

Undervalued compared to fair value


Share Price vs. Fair Value

Undervalued: CURK (€1.09) is trading below our estimate of fair value (€1.78)

Significantly Undervalued: CURK is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: CURK is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: CURK is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate CURK's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CURK is good value based on its PB Ratio (1.2x) compared to the DE Biotechs industry average (3.2x).


Next Steps

Future Growth

How is curasan forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

81.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CURK is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CURK is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CURK is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CURK's revenue (20.4% per year) is forecast to grow faster than the German market (5% per year).

High Growth Revenue: CURK's revenue (20.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: CURK is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has curasan performed over the past 5 years?

-37.9%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: CURK is unprofitable, and losses have increased over the past 5 years at a rate of -37.9% per year.

Accelerating Growth: Unable to compare CURK's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CURK is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Return on Equity

High ROE: CURK has a negative Return on Equity (-101.84%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: CURK is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: CURK is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is curasan's financial position?


Financial Position Analysis

Short Term Liabilities: CURK's short term assets (€4.6M) exceeds its short term liabilities (€4.0M)

Long Term Liabilities: CURK's short term assets (4.6M) exceeds its long term liabilities (571.0K)


Debt to Equity History and Analysis

Debt Level: CURK's debt to equity ratio (37.7%) is considered satisfactory

Reducing Debt: CURK's debt to equity ratio has increased from 2.8% to 37.7% over the past 5 years.


Balance Sheet

Inventory Level: CURK has a high level of physical assets or inventory.

Debt Coverage by Assets: CURK's debt is covered by short term assets (assets are 2.157370x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CURK has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: CURK has less than a year of cash runway if free cash flow continues to reduce at historical rates of -52.2% each year


Next Steps

Dividend

What is curasan's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

company0%marketbottom25%1.5%markettop25%3.8%industryaverage0.8%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate CURK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate CURK's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if CURK's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CURK's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: CURK is not paying a notable dividend for the German market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CURK's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

What is the CEO of curasan's salary, the management and board of directors tenure and is there insider trading?

3.4yrs

Average management tenure


CEO

Torben Sorensen 0

0.08yrs

Tenure

0

Mr. Torben Sorensen serves as Chief Executive Officer at curasan AG since September 16, 2019. He has been a successful, internationally active interim manager and has reputation as a turnaround specialist  ...


Management Age and Tenure

3.4yrs

Average Tenure

Experienced Management: CURK's management team is considered experienced (3.4 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Fabian Peters (49yo)

    Technical Director

    • Tenure: 0yrs
  • Ingo Middelmenne

    Head of Investor Relations

    • Tenure: 0yrs
  • Gregor Siebert

    Head of Marketing & Sales

    • Tenure: 4.5yrs
  • Andrea Weidner

    Head of Corporate Communications

    • Tenure: 0yrs
  • Shane Ray

    President of USA

    • Tenure: 3.4yrs
  • Torben Sorensen

    Chief Executive Officer

    • Tenure: 0.08yrs

Board Members

  • Detlef Wennigsen

    Chairman of the Supervisory Board

    • Tenure: 0yrs
    • Compensation: €28.00k
  • Kurt Berger (53yo)

    Member of Supervisory Board

    • Tenure: 0.08yrs
  • Isabella de Krassny (61yo)

    Deputy Chairman of the Supervisory Board

    • Tenure: 0yrs

Company Information

curasan AG's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: curasan AG
  • Ticker: CURK
  • Exchange: XTRA
  • Founded: 1988
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €9.882m
  • Shares outstanding: 9.07m
  • Website: https://www.curasan.de

Number of Employees


Location

  • curasan AG
  • Lindigstrasse 4
  • Kleinostheim
  • Bavaria
  • 63801
  • Germany

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CURKDB (Deutsche Boerse AG)YesBearer SharesDEEURJul 2000
CURKXTRA (XETRA Trading Platform)YesBearer SharesDEEURJul 2000

Biography

curasan AG, together with its subsidiaries, develops, produces, and markets biomaterials and medical devices for bone and tissue regeneration worldwide. The company specializes in offering biomimetic bone  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/17 20:57
End of Day Share Price2019/10/17 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.